<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="50346">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01999829</url>
  </required_header>
  <id_info>
    <org_study_id>2013-23</org_study_id>
    <secondary_id>2013-23</secondary_id>
    <nct_id>NCT01999829</nct_id>
  </id_info>
  <brief_title>Prevention of Atrial Fibrillation Following Valvular Replacement With Cardiopulmonary Bypass: a Prospective, Randomized Clinical Study Comparing Oral Caffeine With Placebo</brief_title>
  <official_title>Prevention of Atrial Fibrillation Following Valvular Replacement With Cardiopulmonary Bypass: a Prospective, Randomized Clinical Study Comparing Oral Caffeine With Placebo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atrial fibrillation remains a major cause of morbidity following cardiac surgery with
      cardiopulmonary bypass. Many mechanisms have been implicated. Among then, adenosine, a
      strong endogenous vasodilating agent has been involved in cardiac surgery-induced atrial
      fibrillation, via A2A receptors modulation.

      The effects of caffeine on the inducibility of atrial fibrillation are actually well-known,
      leading then to a significant reduction of atrial fibrillation. Moreover, a recent clinical
      study has demonstrated that coffee drinking was inversely associated with total and
      cause-specific mortality.

      The investigators therefore examined the preventive effects of oral caffeine on valvular
      surgery with cardiopulmonary bypass-induced atrial fibrillation. The investigators also
      evaluated prospectively the influence of caffeine on adenosine plasma levels and A2A
      adenosine receptors modulation.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Decrease of 50 % of the incidence of atrial fibrillation</measure>
    <time_frame>24 MONTHS</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>decrease in the use of anti-arrhythmic resuscitation</measure>
    <time_frame>24 MONTHS</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>citrate of caffeine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>citrate of caffeine</intervention_name>
    <arm_group_label>citrate of caffeine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age = 18 years

          -  Surgery valvular settled(adjusted) (plasties or aortic replacement, mitral, tricuspid
             or mixed), under CEC

          -  Period of weaning in caffeine: limitation of the consumption of coffee(café), tea,
             chocolate, in a cup the day before the intervention

          -  Consent of the patients after information

        Exclusion Criteria:

          -  Pregnant or breast-feeding women

          -  Women taking an oral contraception (half-life of the caffeine increased until 3
             times)

          -  Minors(miners) or adults under guardianship

          -  Persons staying in a sanitary or social establishment

          -  Not profitable persons of a national insurance scheme

          -  Private persons of freedom

          -  Persons requiring a surgery of replacement valvular as a matter of urgency

          -  Patients having been treated(handled) by papaverine, dipyridamole, corticoids,
             immunosuppressors or antibiotics during six weeks preceding the date of inclusion

          -  Weighty patient lower than 50 kg or upper to 100 kg or having a body mass index upper
             to 29 Kg / m2

          -  Presence of an active infection, a chronic inflammatory pathology, a lung arterial
             high blood pressure
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>LOIC MONDOLONI</last_name>
    <role>Study Director</role>
    <affiliation>Assistance Publique Hopitaux De Marseille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>laetitia nee</last_name>
    <email>laetitia.nee@ap-hm.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Assistance Publique Hopitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13354</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>laetitia nee</last_name>
      <email>laetitia.nee@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>laetitia nee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>December 2, 2013</lastchanged_date>
  <firstreceived_date>September 26, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Caffeine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
